Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial

McCrimmon R. J., Al Sifri S., EMRAL R., Mohan V., Sauque-Reyna L., Trescoli C., ...Daha Fazla

DIABETES OBESITY & METABOLISM, cilt.23, sa.6, ss.1221-1231, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 6
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1111/dom.14354
  • Dergi Adı: DIABETES OBESITY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1221-1231
  • Anahtar Kelimeler: basal insulin, GLP&#8208, 1 analogue, glycaemic control, insulin therapy, randomized trial, type 2 diabetes, FIXED-RATIO COMBINATION, GLARGINE PLUS LIXISENATIDE, HYPOGLYCEMIA, LIXILAN, METFORMIN, EFFICACY, SAFETY
  • Ankara Üniversitesi Adresli: Evet

Özet

Aim Premix insulin is commonly used in some regions of the world, despite the higher risk of hypoglycaemia and weight gain compared with basal insulin, based on the premise that it offers a simplified insulin regimen. iGlarLixi is a once-daily titratable fixed-ratio formulation that combines basal insulin glargine 100 units/mL (iGlar) and the GLP-1 RA, lixisenatide, which offers a single-injection option for treatment intensification, with improved HbA1c reductions, similar hypoglycaemia risk and more favourable bodyweight profiles over iGlar alone. This randomized controlled study directly compares, for the first time, treatment intensification with iGlarLixi versus premix insulin analogue biphasic insulin aspart 30 (BIAsp 30) in adults with T2D inadequately controlled on basal insulin in combination with one or two oral antihyperglycaemic drugs.